Dr Reddy’s and Nestlé Health Science, a joint venture between Dr. Reddy’s Laboratories and Nestle India, launched Celevida GLP Plus in the domestic market.
It is a specialised product to support optimum nutrition intake and muscle mass maintenance for sustaining metabolic and functional health for people undergoing GLP-1/GIP therapy for management of type 2 diabetes and obesity.
“GLP-1 therapies represent a significant advancement in diabetes and obesity management. However, a clear unmet need remains in supporting patients beyond pharmacological treatment, particularly in addressing nutrition gaps and preserving muscle health during therapy. With Celevida GLP+, we aim to address this gap,’’ M.V. Ramana, CEO, Global Generics at Dr. Reddy’s Laboratories and Director, Dr. Reddy’s and Nestlé Health Science said in a release on Thursday.
Celevida GLP+ is available in a 350 g pack across pharmacies, retail outlets, and leading e-commerce platforms.
GLP-1/GIP therapy refers to a class of medicines that mimic two natural gut hormones—GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)—to help regulate blood sugar, appetite, and body weight.